Trial: 201904078

A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously
Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk


III (Cancer Control)

Principal Investigator

Reimers, Melissa

Disease Site


Learn more about this study at: